Multiple System Atrophy Clinical Trial
Official title:
Identification of Autonomic Failure Patients, Controls and Blood Sampling for Pilot Study
Verified date | October 2016 |
Source | Vanderbilt University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study is to identify 15 patients with autonomic failure and obtain blood
samples for RNA from those participants and 15 control subjects within the same age range.
The stabilized blood samples, along with a limited data set, will be shipped to Western
Michigan University where the actual laboratory analysis (a separate study) of the samples
will take place.
Unique genetic inscriptions, called gene expression signatures, are currently being
identified for many diseases, including neurological diseases. The secondary goal of this
study is to support the research being done at WMU and they try to look for MSA-specific
signs are present in whole blood samples of MSA patients at late-stages of the disease. This
is a pilot study that has a long term goal (through additional studies) a MSA-specific gene
expression signature for the development of a diagnostic test for this disease that can be
used in the future. Other patient groups with autonomic failure, characterized by
significant drop in blood pressure on standing, will also be included in this study, to look
for similar genetic inscriptions.
This pilot study is expected to last for 2 years. The investigators at WMU will need some
de-identified health Information about the subjects, including their age at diagnosis, age
(when sample drawn) and list of their medications
Status | Completed |
Enrollment | 30 |
Est. completion date | February 2009 |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 50 Years to 75 Years |
Eligibility |
Inclusion Criteria for patients: - presumed or probably diagnosis of autonomic disorder characterized by orthostatic hypotension - age between 50 - 75 years - Male or female - Able and willing to provide consent Inclusion Criteria for controls: - Absence of neurological disorder - age between 50 - 75 years - Male or female - Able and willing to provide consent Exclusion Criteria: - inability to provide consent |
N/A
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University | Western Michigan University |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03593512 -
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Recruiting |
NCT02897063 -
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
|
Phase 1 | |
Not yet recruiting |
NCT00758849 -
Fipamezole in Neurogenic Orthostatic Hypotension
|
Phase 2 | |
Completed |
NCT01155492 -
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04431713 -
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
|
Phase 2 | |
Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
Recruiting |
NCT05121012 -
Synaptic Loss in Multiple System Atrophy
|
||
Terminated |
NCT03589976 -
A Futility Trial of Sirolimus in Multiple System Atrophy
|
Phase 2 | |
Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
Recruiting |
NCT04680065 -
GDNF Gene Therapy for Multiple System Atrophy
|
Phase 1 | |
Completed |
NCT03753763 -
Safinamide for Multiple System Atrophy (MSA)
|
Phase 2 | |
Recruiting |
NCT04250493 -
Insulin Resistance in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT06072105 -
Medical Decision Making in Multiple System Atrophy
|
N/A | |
Terminated |
NCT02149901 -
Water and Sudafed in Autonomic Failure
|
Early Phase 1 | |
Terminated |
NCT00997672 -
Lithium in Multiple System Atrophy
|
Phase 2 |